Vanguard Group Inc Gain Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GANX
# of Institutions
28Shares Held
3.07MCall Options Held
0Put Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.13 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.09 Million0.04% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL450KShares$864,0000.0% of portfolio
-
Hohimer Wealth Management, LLC330KShares$633,6000.1% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$522,1860.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $22.8M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...